Wedoany.com Report-Dec.31, Mabwell (688062.SH), an innovative biopharmaceutical company with a full industry chain layout, announced that its Adalimumab Injection 9MW0113 (domestic brand name: Junmaikang®) has received marketing approval from the Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan, BPOM). This marks the third overseas marketing approval obtained by Mabwell this year.

9MW0113, co-developed by Mabwell and Junshi Biosciences, is the first adalimumab biosimilar independently developed in China to be approved by the Indonesian BPOM. Mabwell has signed formal cooperation agreements for 9MW0113 in over ten countries and has submitted registration application documents to several countries, including Jordan and Peru.

Hu Huiguo, Director, Senior Vice President, and Secretary of the Board of Mabwell, stated: "Indonesia is the most populous country in Southeast Asia, with growing pharmaceutical demands. As a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), Indonesia maintains a rigorous drug quality review system. This approval represents significant recognition for Mabwell's adalimumab in the Southeast Asian market. In the future, we will continue to promote the commercialization of the product in more countries, further enhancing its global accessibility to meet the needs of more patients."